HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A phase I trial of chlorambucil administered in short pulses in patients with advanced malignancies.

Abstract
We carried out a phase I trial with chlorambucil. Thirty patients with advanced cancer were entered in six dose levels: 36, 48, 60, 84, 108, and 144 mg/m2. The drug was given in six divided oral doses every 6 hours and the regimen was repeated every 3 weeks. The median age was 62 years (31-84), median Karnofsky performance status (KPS) 60 (40-90). All patients but one had received prior radiation therapy, chemotherapy, or both. Central nervous system toxicity was dose limiting, occurring in 5 of 6 patients at 144 mg/m2. It was characterized by transient seizures, hallucinations, lethargy, stupor, and coma. Metoclopramide was successful in controlling nausea and vomiting, which was severe if the antiemetic was not used. Leukopenia (3 patients) and thrombocytopenia (2 patients) were mild. One patient with colorectal carcinoma had a minor response, and two patients with non-small cell lung cancer had stable disease. A safe dose for phase II trials is 108 mg/m2 in six 6-hourly oral doses.
AuthorsM S Blumenreich, T M Woodcock, E J Sherrill, S P Richman, P S Gentile, B E Epremian, T T Kubota, J C Allegra
JournalCancer investigation (Cancer Invest) Vol. 6 Issue 4 Pg. 371-5 ( 1988) ISSN: 0735-7907 [Print] England
PMID3179770 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Chlorambucil
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Marrow (drug effects)
  • Brain (drug effects)
  • Chlorambucil (adverse effects)
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: